Global Market for ELISA is Projected to Reach US$165 Million by 2020
Rising Investments in Clinical Immunology Drives the Enzyme-Linked
Immunosorbent Assay Market, According to New Report by Global Industry Analysts, Inc.
GIA launches
comprehensive analysis of industry segments, trends, growth drivers, market
share, market size and demand forecasts on the Enzyme-Linked Immunosorbent
Assay (ELISA) markets. Global
market for ELISA is projected to reach US$165 million by 2020, driven by
its continued use as a secondary validation technique, and increasing investments
in research related to immunology and medicine.
Enzyme-Linked
Immunosorbent Assay (ELISA) or Enzyme Immunoassay (EIA) is a bio-chemical
method with immunological applications that is used in the detection of
antigens and antibodies in biological samples. ELISA, over the decades, witnessed
widespread popularity in the rapidly changing life sciences and drug discovery
market. Sales of ELISA products, in the short to medium term, are expected to
come largely from the use of ELISA as a secondary validation process by
multiplex customers. This is largely due to the quality and established
credential of Research ELISA products. Give, its cost effectiveness, ELISA
products are preferred by laboratories and researchers dealing with less number
of analytes and high sensitivity of assays. Another factor driving growth of
ELISA in the immunoassay market is the development of automated platforms.
These platforms, specifically designed for running ELISA, offer improved
performance, increased productivity, greater sensitivity, better uniformity,
improved speed, reduced assay time, cycle time, higher throughput,
miniaturization, elimination of time consuming wash steps, and the flexibility
to adapt a range of assays/protocol.
In addition,
the relatively low penetration of fully automated ELISA offers a solid business
case for cellular ELISA manufacturers to tap into the large untapped potential.
New technologies, such as the development of new tests that simplify the
process of autoantigen extraction and subsequent protein purification, offer
additional growth prospects for ELISA. The technique, which involves use of
in-vitro labeling of autoantigens for measuring autoantibodies, is expected to
find significant application in detecting dermatomyositis and other
myositis-specific autoantibodies. Current progress in the area of ELISA tests
is being made with the development of NS1 antigen-capture ELISA, which helps
efficient clinical management and control of West Nile Virus. These advances
could further increase adoption of ELISA.
Despite the
opportunities for growth, the market faces numerous challenges in equal
measure. The last couple of years witnessed the threat of substitution by new
technologies, particularly multiplex proteomic array platforms. The growing
preference for multiplex proteomic arrays has been cannibalizing the popularity
of ELISA. In addition to the competitive threat posed by multiplex assays,
manufacturers have been facing a major challenge in the form of increasing commoditization
of ELISA products. Commoditization has intensified pricing pressures for
manufacturers. To counter the challenges, manufacturers are targeting niche
markets and are focusing on the development of innovative products.
As stated by
the new market research report on Enzyme-Linked Immunosorbent Assay (ELISA), the
United States represents the largest market for Research ELISA worldwide. Asia-Pacific
ranks as the fastest growing regional market with a projected CAGR of 2% over
the analysis period. Increasing medical tourism and demand for cost effective
biochemical screening technologies are the key factors driving growth in the
region.
Major players
covered in the report include American Laboratory Products Company (ALPCO), BD
Biosciences, BioMérieux SA, Bio-Rad Laboratories Inc., EMD Millipore Corp.,
Life Technologies Corporation, Ortho-Clinical Diagnostics Inc., R&D Systems
Inc., Thermo Fisher Scientific Inc., and ZEUS Scientific Inc.
Comments
Post a Comment